While the stock rose 7% in 2024, that gain was split between a 318% rocket ride higher from where it ended 2023 (at $28.43) to its March 13 record close of $118.81, and the 74% plunge from there to ...
The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...
Taking care of my personal health remains a top priority, however, I have also turned my attention to encouraging others to prioritize their health by raising awareness of my experiences. I understand ...
The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...
There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their ...
Jones Financial Companies Lllp increased its stake in Vertex Pharmaceuticals by 75.5% in Q4, now holding 2,468 shares valued ...
2d
Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback